BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang R, Yuan T, Wang J, Chen Y, Zhao J, Li M, Fang L, Du G. Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective. Pharmacological Research 2022;180:106238. [DOI: 10.1016/j.phrs.2022.106238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang H, Xu Y, Gao J, Li M, Fa J, Ding X, Yang C, Zhang L, Luan Y, Xia Y, Wang M, Li Q, Xing L, Liu Z. Divergent indicator changes in different exercise states in non-hypertensive individuals and patients with hypertension.. [DOI: 10.21203/rs.3.rs-2457714/v1] [Reference Citation Analysis]
2 Abdulkareem AO, Tiwari P, Lone ZR, Iqbal H, Gupta S, Jha RK, Chanda D, Jagavelu K, Hanif K. Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension. European Journal of Pharmacology 2023. [DOI: 10.1016/j.ejphar.2023.175558] [Reference Citation Analysis]
3 Silva GF, da Silva JS, de Alencar AKN, de Moraes Carvalho da Silva M, Montagnoli TL, de Souza Rocha B, de Freitas RHCN, Sudo RT, Fraga CAM, Zapata-sudo G. Novel p38 Mitogen-Activated Protein Kinase Inhibitor Reverses Hypoxia-Induced Pulmonary Arterial Hypertension in Rats. Pharmaceuticals 2022;15:900. [DOI: 10.3390/ph15070900] [Reference Citation Analysis]
4 Huang L, Zhang H, Liu Y, Long Y. The Role of Gut and Airway Microbiota in Pulmonary Arterial Hypertension. Front Microbiol 2022;13:929752. [DOI: 10.3389/fmicb.2022.929752] [Reference Citation Analysis]
5 Rodrigues GD, Vicenzi M, Bellocchi C, Beretta L, Carandina A, Tobaldini E, Carugo S, Montano N. The Systolic Pulmonary Arterial Pressure Liaises Impaired Cardiac Autonomic Control to Pro-inflammatory Status in Systemic Sclerosis Patients. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.899290] [Reference Citation Analysis]